Roivant Sciences (NASDAQ:ROIV) Sets New 52-Week High on Analyst Upgrade

Roivant Sciences Ltd. (NASDAQ:ROIV) hit a new 52-week high during mid-day trading on Tuesday after TD Cowen raised their price target on the stock from $50.00 to $55.00. TD Cowen currently has a buy rating on the stock. Roivant Sciences traded as high as $41.62 and last traded at $39.0310, with a volume of 710937 shares changing hands. The stock had previously closed at $34.93.

Other analysts also recently issued reports about the company. Cantor Fitzgerald reissued an “overweight” rating on shares of Roivant Sciences in a research note on Tuesday, August 25th. Guggenheim lifted their target price on Roivant Sciences from $42.00 to $46.00 and gave the company a “buy” rating in a research report on Wednesday. Bank of America reiterated a “neutral” rating on shares of Roivant Sciences in a report on Friday, July 31st. Piper Sandler reissued an “overweight” rating on shares of Roivant Sciences in a research report on Thursday, May 21st. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Roivant Sciences in a research note on Wednesday, August 19th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $40.62.

Insider Activity

In related news, insider Mayukh Sukhatme sold 284,707 shares of the firm’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $36.25, for a total value of $10,320,628.75. Following the sale, the insider directly owned 18,630,739 shares of the company’s stock, valued at $675,364,288.75. This trade represents a 1.51% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Daniel Gold sold 800,000 shares of Roivant Sciences stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $34.55, for a total value of $27,640,000.00. Following the sale, the director directly owned 13,701,546 shares of the company’s stock, valued at approximately $473,388,414.30. This trade represents a 5.52% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 3,055,913 shares of company stock worth $107,261,258. 8.80% of the stock is owned by corporate insiders.

Key Stories Impacting Roivant Sciences

Here are the key news stories impacting Roivant Sciences this week:

• Positive Sentiment: Roivant’s Pulmovant unit reported positive Phase 2 PHocus results for mosliciguat in pulmonary hypertension associated with interstitial lung disease (PH-ILD). The treatment produced a 56.3% placebo-adjusted reduction in pulmonary vascular resistance, supporting the drug’s potential in a serious disease with substantial unmet need. Roivant PHocus study announcement
• Positive Sentiment: Roivant has started the Phase 3 PHrontier trial, advancing mosliciguat toward a potential registration-enabling study. The transition to late-stage development reduces some development uncertainty and increases the potential value of the program. Mosliciguat Phase 3 trial report
• Positive Sentiment: Analysts raised their price targets while maintaining buy ratings: Jefferies increased its target to $52 from $42, and HC Wainwright raised its target to $47 from $41. These revisions indicate increased confidence in Roivant’s pipeline and commercial prospects.
• Positive Sentiment: Unusually heavy call-option activity and reports that hedge-fund holdings rose 41% added to bullish trading momentum, although options activity is a market-positioning signal rather than a fundamental change. Roivant hedge fund holdings report
• Positive Sentiment: Roivant and partner Priovant are also commercializing Lisraya, described as the first oral FDA-approved treatment for dermatomyositis, with a reported list price of $35,000 per 30-day supply. The launch creates another potential revenue stream, though uptake and reimbursement remain important uncertainties.
• Neutral Sentiment: Management presented at the Wells Fargo and Cantor Fitzgerald healthcare conferences, giving investors additional updates on the pipeline and strategy. The available reports do not identify a separate material announcement from those presentations. Cantor Fitzgerald conference transcript

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. SBI Securities Co. Ltd. raised its holdings in Roivant Sciences by 1,740.3% in the 4th quarter. SBI Securities Co. Ltd. now owns 1,233 shares of the company’s stock worth $27,000 after purchasing an additional 1,166 shares in the last quarter. Allworth Financial LP raised its stake in Roivant Sciences by 48.1% during the third quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock valued at $27,000 after buying an additional 583 shares during the last quarter. Kestra Advisory Services LLC bought a new stake in Roivant Sciences in the fourth quarter worth $47,000. Parallel Advisors LLC boosted its holdings in Roivant Sciences by 33.7% in the first quarter. Parallel Advisors LLC now owns 2,065 shares of the company’s stock worth $57,000 after acquiring an additional 520 shares in the last quarter. Finally, CIBC Private Wealth Group LLC grew its stake in shares of Roivant Sciences by 7,614.3% in the fourth quarter. CIBC Private Wealth Group LLC now owns 2,700 shares of the company’s stock worth $59,000 after acquiring an additional 2,665 shares during the last quarter. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Roivant Sciences Trading Up 0.8%

The firm has a market capitalization of $30.20 billion, a P/E ratio of -78.89 and a beta of 1.12. The business’s 50 day simple moving average is $35.56 and its two-hundred day simple moving average is $31.46.

Roivant Sciences (NASDAQ:ROIV) last issued its earnings results on Friday, August 7th. The company reported ($0.26) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.04. The business had revenue of $1.44 million during the quarter, compared to analyst estimates of $2.06 million. Roivant Sciences had a negative return on equity of 22.94% and a negative net margin of 3,534.96%. Analysts predict that Roivant Sciences Ltd. will post -2 EPS for the current fiscal year.

About Roivant Sciences

Roivant Sciences Ltd. is a biopharmaceutical company focused on discovering, developing and commercializing medicines for patients with significant unmet medical needs. The company concentrates on areas including immunology, dermatology, oncology and other specialty conditions, using a combination of internally developed programs, external licensing and strategic acquisitions.

Roivant organizes many of its drug-development activities through subsidiary companies known as “Vants.” These businesses are designed to advance individual therapeutic programs or groups of related assets, while Roivant provides operational, scientific and strategic support.